Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Editas Medicine Inc shares valued at $3,361 were sold by O’Neill Gilmore Neil on Dec 03 ’24. At $2.08 per share, O’Neill Gilmore Neil sold 1,618 shares. The insider’s holdings dropped to 312,106 shares worth approximately $0.38 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Mei Baisong sold 541 shares, netting a total of over 1,124 in proceeds. Following the sale of shares at $2.08 each, the insider now holds 133,354 shares.
Before that, Mei Baisong had sold 518 shares from its account. In a trade valued at $1,774, the EVP, CHIEF MEDICAL OFFICER traded Editas Medicine Inc shares for $3.42 each. Upon closing the transaction, the insider’s holdings decreased to 518 shares, worth approximately $0.16 million.
As published in a research note from JP Morgan on December 16, 2024, Editas Medicine Inc [EDIT] has been rated down from a Neutral to an Underweight. Analysts at Truist downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in mid December. As of December 13, 2024, Stifel has decreased its “Buy” rating to a “Hold” for EDIT. Earlier on December 13, 2024, Chardan Capital Markets downgraded its rating. Their new recommendation was “a Neutral” for EDIT stock which previously was a “a Buy”.
Analyzing EDIT Stock Performance
During the last five days, there has been a drop of approximately -20.39%. Over the course of the year, Editas Medicine Inc shares have dropped approximately -88.06%. Shares of the company reached a 52-week high of $11.5800 on 02/28/24 and a 52-week low of $1.2000 on 12/24/24. A 50-day SMA is recorded $2.5240, while a 200-day SMA reached $4.4688. Nevertheless, trading volume fell to 1.58 million shares from 2.65 million shares the previous day.
Support And Resistance Levels for Editas Medicine Inc (EDIT)
According to the 24-hour chart, there is a support level at 1.1867, which, if violated, would cause prices to drop to 1.1633. In the upper region, resistance lies at 1.2467. The next price resistance is at 1.2833. RSI (Relative Strength Index) is 22.25 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.3976, which suggests the price will decrease in the coming days. Percent R is at 99.14%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
